Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-Aged Men - Data from the PROBASE Trial - Articles - Oncology · Hematology

Genitourinary Cancer

Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial

Eur Urol

Vigneswaran HT, Palsdottir T, Micoli C, Tilki D, Lin D, Cooperberg M, Eggener S, Falagario UG, Möller A, Aly M, Akre O, Wiklund P, Egevad L, Grönberg H, Nordström T, Eklund M

doi: 10.1016/j.eururo.2025.10.001

Genitourinary Cancer

Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Eur Urol

Nguyen DD, Tadayon Najafabadi B, Lin L, Kwong JCC, Miller E, Zlotta AR, Fleshner NE, Hird AE, Lofters AK, Wallis CJD, Rosella LC, Dahm P, Guyatt G, Kulkarni GS

doi: 10.1016/j.eururo.2026.04.005

Genitourinary Cancer

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials

Lancet Oncol

Kayani M, Murphy L, Dutey-Magni P, Howlett S, Sachdeva A, Padden-Modi M, Abdel-Aty H, Brown LC, Amos CL, Chan K, Gilbert DC, Langley RE, Brown M, Sydes MR, Parker CC, STAMPEDE Collaborators, Cross W, Malik Z, Varughese M, Turco F, Millman R, Matheson D, Gillessen S, Clarke NW, Parmar MKB, James ND, Attard G

doi: 10.1016/S1470-2045(26)00066-5

Genitourinary Cancer

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer-Specific Mortality in Localized Prostate Cancer

Prostate

Falkenbach F, Di Bello F, Peñaranda NR, Longoni M, Marmiroli A, Le QC, Tian Z, Goyal JA, Longo N, Micali S, Briganti A, De Cobelli O, Chun FKH, Saad F, Shariat SF, Budäus L, Graefen M, Karakiewicz PI

doi: 10.1002/pros.70045

Genitourinary Cancer

Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer

Prostate Cancer Prostatic Dis

Morgans AK, Wallis CJD, Halabi S, Armstrong AJ, Adorjan P, Ghadessi M, Verholen F, Grimm MO

doi: 10.1038/s41391-026-01076-w

Genitourinary Cancer

Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide

Prostate

Martínez Osorio CA, Sopeña Sutil R, Vilaseca Cabo A, Linares Espinós E, Ramírez Backhaus M, Gómez Rivas J, Costa Planells M, Martinez Breijo S, Picola Brau N, Domínguez Esteban N, Muñoz Rodríguez J, Sanchís Bonet A, Guijarro Cascales A, Beamud Cortés M, Servian Vives P, de la Morena Gallego JM, Pérez Márquez M, García Sanz M, Ramón Alemán J, Zamora Horcajada Á, Rodríguez Part V, Hassi Roman M, Rodriguez Concha C, Rios González E, de Pablos-Rodríguez P

doi: 10.1002/pros.70040

Genitourinary Cancer

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

J Clin Oncol

Armstrong AJ, Azad AA, Iguchi T, Stenzl A, Mottet N, Russell D, Rosales M, Haas GP, Saad F, Hussain M, Sternberg CN

doi: 10.1200/JCO-24-02829

Genitourinary Cancer

Effect of [(68)Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial

Lancet Oncol

Buteau JP, Moon D, Fahey MT, Roberts MJ, Ayati N, Papa N, Murphy DG, Kasivisvanathan V, Dhillon HM, Du YT, Dundee P, Foudoulis J, Hennes D, Hutton AC, Idiare J, Jack G, Kamath S, Lee SN, Lee SF, Lee ST, Leslie S, Levy SM, Link E, Mitchell C, Morigi JJ, Nguyen A, Olphert J, Patel MI, Pattison DA, Pearce A, Perera M, Thanigasalam R, Thomson A, Yaxley J, Thompson J, Hofman MS, Emmett L, PRIMARY2 Trial Investigators

doi: 10.1016/S1470-2045(26)00120-8

Genitourinary Cancer

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry

Eur Urol

Karpinski MJ, Hoberück S, Fendler WP, Civan C, Bundschuh RA, Thomas C, Bjartell A, Trägårdh E, Soeterik TFW, Evangelista L, Vondrak A, Rasul S, Forner L, Giorgio AD, Scholtissek H, Miksch J, Holzgreve A, Lanfranchi F, Rahbar K, Hofman MS, Rauscher I, Güven O, Eiber M, Ayati N, Umutlu L, Herrmann K, Hadaschik B, Emmett L

doi: 10.1016/j.eururo.2025.10.013

Related content

Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial

Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer-Specific Mortality in Localized Prostate Cancer

Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer

Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

Effect of [(68)Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry